Ask ten med spa medical directors how they structure a semaglutide-plus-BPC-157 research protocol and you'll get ten different answers. Some are anchored in published trial data. Most are anchored in whatever the last conference speaker said. As peptide-based research protocols move from the fringe to the center of aesthetic and metabolic practice economics, the gap between what practitioners are doing and what the underlying pharmacology supports is widening — and it's becoming a liability. This piece is a working framework for the stacks we see most often in physician-supervised research settings, with an emphasis on titration logic, frequency, and the sourcing standards that make any protocol defensible.
Why Dosing Frameworks Matter More in 2025
The regulatory temperature around compounded and research peptides has climbed sharply. The FDA's removal of semaglutide and tirzepatide from the shortage list, combined with growing state board scrutiny of med spa prescribing patterns, means that clinics can no longer rely on informal, provider-to-provider dosing folklore. Every protocol needs a written rationale, a titration schedule, and documentation of source material — not because the paperwork itself is protective, but because the underlying discipline it enforces is.
There is also a shift in the literature itself. Early GLP-1 protocols assumed weekly-forever dosing. Recent case series data suggests that reduced-frequency maintenance may preserve outcomes while reducing side-effect burden and cost [3]. That single shift — from weekly induction to reduced-frequency maintenance — reframes how a med spa should think about the entire trajectory of a metabolic research program.
The Four Stacks We See Most Often
In our distribution work with licensed clinics, four combinations dominate research protocol requests: (1) GLP-1 receptor agonists paired with a lean-mass-preserving agent; (2) growth hormone secretagogues stacked for recovery and body composition research; (3) tissue-repair combinations centered on BPC-157 and TB-500; and (4) aesthetic-adjacent stacks combining GHK-Cu with melanocortin analogs. Each has its own dose-response curve, its own tolerability profile, and its own set of practical failure modes.
Stack 1: GLP-1 + Lean Mass Preservation
The dominant metabolic stack in med spa research remains a GLP-1 or dual agonist (semaglutide, tirzepatide, retatrutide in select programs) combined with an agent intended to attenuate lean mass loss — most commonly a growth hormone secretagogue such as ipamorelin or a CJC-1295/ipamorelin combination. The clinical rationale is straightforward: GLP-1 agonists reliably produce 15–20% total body weight reduction at target dose, but roughly 25–40% of that loss is fat-free mass. In a cosmetic practice, that trade-off is a problem.
The Wong et al. case series is worth pausing on. In a cohort maintained on reduced-frequency GLP-1 dosing after achieving target weight, participants preserved body composition improvements and metabolic syndrome markers across the observation window [3]. The operational implication for a med spa is significant: rather than escalating patients indefinitely to the maximum labeled dose and holding them there, a research protocol structured around induction, plateau confirmation, and then a step-down to every-other-week or monthly maintenance may deliver equivalent durability with better tolerability and lower monthly cost per patient.
A defensible titration frame for semaglutide research protocols typically opens at 0.25 mg weekly for four weeks, escalates by 0.25 mg increments every four weeks based on tolerability, and holds at the lowest dose that produces the target weight trajectory — not the maximum tolerated dose. For tirzepatide, the analog is 2.5 mg weekly with 2.5 mg step-ups. The Wong data supports considering a maintenance transition once patients have held target weight for 12 weeks [3].
Stack 2: Growth Hormone Secretagogue Combinations
CJC-1295 (with or without DAC) paired with ipamorelin remains the workhorse GHRH/GHRP research combination. The mechanistic pairing is deliberate: CJC-1295 provides a sustained GHRH signal, while ipamorelin delivers a pulsatile ghrelin-receptor-mediated GH release without the cortisol or prolactin elevation seen with earlier GHRPs like GHRP-6. Typical research doses cluster around 100–300 mcg of each component, administered subcutaneously in the evening to align with endogenous GH pulsatility.
The frequency question — nightly versus five-nights-on/two-off — is not settled in the literature, and honest practitioners should say so. The five-on/two-off cadence is often justified on receptor sensitization grounds, though the human data supporting that specific schedule is thin. What is clear is that continuous supraphysiologic GH signaling produces the same downregulation problems seen with any receptor system, and that dose escalation without a clear endpoint is a red flag in any research protocol.
Stack 3: Tissue Repair — BPC-157 and TB-500
BPC-157 and thymosin beta-4 (TB-500) are the most-requested tissue-repair research peptides in aesthetic and orthobiologic-adjacent practices. The preclinical literature is genuinely interesting — angiogenic effects, fibroblast migration modulation, tendon and ligament healing signals in rodent models — but human RCT data remains limited. This is a category where the compliance framing matters most: these are research compounds studied in the context of tissue repair, not treatments for any specific injury or condition.
Common research doses cluster around 250–500 mcg BPC-157 daily and 2–5 mg TB-500 weekly, with cycling of 4–8 weeks on followed by an off period. Local subcutaneous administration proximate to the tissue of interest is common, though systemic effects are the stated rationale in most protocols.
Stack 4: Aesthetic Adjuncts
GHK-Cu (copper tripeptide) for skin and hair research protocols, often combined with melanocortin analogs in pigmentation-focused work, rounds out the top-four. GHK-Cu is unusual in that it has decades of topical cosmetic literature behind it; the injectable research protocols are a newer application. Doses in the 1–2 mg range subcutaneously, two to three times weekly, are typical in current research use.
The Research: What the Data Actually Supports
The most important recent data point for med spa metabolic programs is the reduced-frequency GLP-1 case series from Wong and colleagues [3]. The study followed patients transitioned from weekly to reduced-frequency dosing after achieving target weight and documented preservation of weight, body composition, and metabolic syndrome improvements across the follow-up period. This is a case series, not an RCT, and the authors are appropriately measured — but the signal is consistent with what we hear anecdotally from clinics tracking their own outcomes.
The broader lesson embedded in that paper is one that peptide research more generally is starting to internalize: dose-response is not monotonic, and the assumption that more frequent administration produces better outcomes is a hypothesis to be tested, not a principle to be assumed. The same lesson has emerged in oncology dosing — from repeat-dose intravesical gene therapy protocols where the optimal interval is empirically derived rather than intuited [1], to targeted combination regimens where the sequencing and frequency of each agent materially affect efficacy [2, 4]. Peptide research protocols in a med spa setting deserve the same rigor, scaled appropriately.
It is also worth noting that in immunologic contexts, durability of effect after dose reduction has been demonstrated in unrelated therapeutic areas — for instance, sublingual immunotherapy protocols where maintenance dosing preserves the tolerance induced during buildup [5]. The mechanistic details differ entirely, but the conceptual point is the same: induction dosing and maintenance dosing are two different clinical problems, and treating them identically wastes drug and patient tolerance.
Clinical Considerations for Protocol Design
A well-constructed peptide research protocol in a med spa setting has, at minimum, five documented elements: a starting dose with rationale, a titration rule tied to objective endpoints, a maximum dose ceiling, a stopping rule for adverse effects, and a maintenance or off-ramp plan. The absence of any one of these is a signal that the protocol was assembled rather than designed.
Titration Anchored to Endpoints, Not Time
The most common error we see is time-based titration divorced from response. A patient who has lost 8% of body weight at week 12 on the starting dose of semaglutide does not need a dose escalation — they are on the response curve. Escalating anyway increases the side-effect burden without a clear efficacy rationale. Titration should be triggered by inadequate response at a defined check-in, not by the calendar.
Stacking Logic and Additive Toxicity
When two peptides are combined, the assumption should be that side-effect profiles are additive until demonstrated otherwise. GLP-1 nausea plus GHRP-mediated appetite stimulation is a common example where the interaction is not clean. Building a stack means having a plan for which agent is de-escalated first when tolerability fails.
Documentation and Consent
Every research protocol should carry documentation that the patient understands the research nature of the compound, the specific dose and frequency, the expected duration, and the criteria for continuation or discontinuation. This is both a compliance requirement and a clinical discipline — protocols that cannot be written down clearly usually cannot be defended clearly either.
What to Look for in a Peptide Source
Sourcing is where most med spa programs are quietly exposed. The market is flooded with material sold as 'research grade' that has never been characterized against a defensible specification. A clinic that has built careful protocols on top of uncharacterized material has built on sand.
Minimum sourcing standards for any peptide entering a physician-supervised research protocol should include: a certificate of analysis (COA) from an independent third-party laboratory, with mass spectrometry confirming identity and HPLC quantifying purity (>98% is the working standard for most research peptides); documentation of the synthesis facility's quality system, ideally cGMP-aligned; endotoxin testing for any material intended for parenteral research use; and lot-level traceability so that a specific vial can be tied to a specific synthesis batch and its associated COA.
The failure mode we see most often is a clinic that has a COA — but the COA is from the manufacturer's internal lab, is not lot-specific, and predates the material by six months. That is not documentation; that is decoration. Independent, lot-specific, current COAs are the standard.
Why This Matters for Your Practice
The economics of a well-run peptide research program in a med spa are compelling, but they are also fragile. A single adverse event tied to uncharacterized material, a single state board inquiry about undocumented dosing decisions, or a single insurance carrier deciding that peptide protocols are out of scope for the practice's coverage — any of these can erase a year of program revenue overnight.
The clinics that will still be running these programs in three years are the ones that treat protocol design and sourcing as core clinical infrastructure, not as marketing surface. That means written titration frames, documented sourcing standards, ongoing outcome tracking, and a willingness to update protocols when the literature moves — as it clearly has on reduced-frequency GLP-1 maintenance [3].
It also means being honest with patients about what these compounds are and are not. They are research-grade materials used in physician-supervised protocols. They are not miracle cures, and the literature does not support marketing them as such. Practices that hold that line will find that it is not a limitation on their business — it is the foundation of a defensible one.
The framework above is a starting point, not a prescription. Every practice will refine it against its own patient population, its own outcome data, and its own clinical judgment. But the discipline of having a framework at all — writing it down, defending each decision, and updating it as evidence accumulates — is what separates a clinical research program from a peptide reseller with a medical license attached.